A BILL 
To advance treatment and cures for blindness and other 
retinal conditions and to promote competitiveness in the 
United States through a pilot program to increase fund-
ing for translational research, and for other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Faster Treatments and 
4
Cures for Eye Diseases Act’’. 
5
SEC. 2. DEFINITIONS. 
6
For purposes of this Act: 
7
21:50 May 17, 2019
H2620
2 
•HR 2620 IH
(1) 
APPLICABLE
CONGRESSIONAL
COMMIT-
1
TEES.—The term ‘‘applicable congressional commit-
2
tees’’ means the Committees on Energy and Com-
3
merce and Financial Services of the House of Rep-
4
resentatives and the Committees on Banking, Hous-
5
ing, and Urban Affairs and Health, Education, 
6
Labor, and Pensions of the Senate. 
7
(2) APPROPRIATE
FEDERAL
BANKING
AGEN-
8
CY.—The term ‘‘appropriate Federal banking agen-
9
cy’’ has the meaning given that term in section 3 of 
10
the Federal Deposit Insurance Act (12 U.S.C. 
11
1813). 
12
(3) COST.—The term ‘‘cost’’ has the meaning 
13
given to the term ‘‘cost of a loan guarantee’’ in sec-
14
tion 502(5)(C) of the Federal Credit Reform Act of 
15
1990 (2 U.S.C. 661a(5)(C)). 
16
(4) DEPOSITORY INSTITUTION; DEPOSITORY IN-
17
STITUTION HOLDING COMPANY.—The term ‘‘deposi-
18
tory institution’’ and ‘‘depository institution holding 
19
company’’ have the meaning given those terms under 
20
section 3 of the Federal Deposit Insurance Act (12 
21
U.S.C. 1813). 
22
(5) EYE BOND.—The term ‘‘eye bond’’ means a 
23
bond— 
24
21:50 May 17, 2019
H2620
3 
•HR 2620 IH
(A) issued by an issuer pursuant to this 
1
Act; 
2
(B) the proceeds of which are used to fund 
3
projects selected under section 6(b)(1), except 
4
as otherwise described in this Act; and 
5
(C) that complies with the regulations 
6
issued under section 4. 
7
(6) FUNDED
PROJECT.—The term ‘‘funded 
8
project’’ means a translational research project that 
9
is selected to be funded using the proceeds of an eye 
10
bond. 
11
(7) GUARANTEE.—The term ‘‘guarantee’’ has 
12
the meaning given to the term ‘‘loan guarantee’’ in 
13
section 502 of the Federal Credit Reform Act of 
14
1990 (2 U.S.C. 661a) and includes a loan guarantee 
15
commitment (as defined in such section 502). 
16
(8) ISSUER.—The term ‘‘issuer’’ means an enti-
17
ty that— 
18
(A) is a depository institution, a depository 
19
institution holding company, or a broker or 
20
dealer registered with the Securities and Ex-
21
change Commission; 
22
(B) complies with the schedule for the 
23
issuance of eye bonds established under section 
24
3(c); and 
25
21:50 May 17, 2019
H2620
4 
•HR 2620 IH
(C) complies with the regulations issued 
1
under section 5. 
2
(9) PROGRAM.—The term ‘‘Program’’ means 
3
the Eye Bond Pilot Program established under sec-
4
tion 3. 
5
(10) 
SECRETARY.—The 
term 
‘‘Secretary’’ 
6
means the Secretary of Health and Human Services, 
7
except in references to the Secretary of the Treas-
8
ury. 
9
(11) STATE.—The term ‘‘State’’ means— 
10
(A) each State of the United States; 
11
(B) the District of Columbia; 
12
(C) the Commonwealth of Puerto Rico; 
13
and 
14
(D) any other territory or possession of the 
15
United States. 
16
(12) TRANSLATIONAL
RESEARCH.—The term 
17
‘‘translational research’’— 
18
(A) means any research project that is de-
19
signed to cure vision blindness and any condi-
20
tions attendant to vision impairment that are, 
21
as determined by the Director of the National 
22
Eye Institute, congenital to the vision impair-
23
ment and not incidental to vision impairment or 
24
caused by vision impairment; 
25
21:50 May 17, 2019
H2620
5 
•HR 2620 IH
(B) includes projects designed to cure— 
1
(i) hearing impairment genetically 
2
linked to vision impairment, such as Usher 
3
Syndrome; 
4
(ii) retinal degenerative diseases such 
5
as retinitis pigmentosa, macular degenera-
6
tion, and Usher Syndrome; 
7
(iii) vision trauma due to injury such 
8
as that experienced by wounded veterans; 
9
(iv) glaucoma; 
10
(v) optic nerve disorders that result in 
11
vision impairment or blindness, such as 
12
morning glory syndrome; and 
13
(vi) diabetic reinopathy; and 
14
(C) subject to subparagraph (B)(vi), does 
15
not include projects designed to cure any under-
16
lying disease or condition whose symptoms may 
17
include vision impairment, such as diabetes. 
18
SEC. 3. EYE BOND PILOT PROGRAM. 
19
(a) ESTABLISHMENT.—Not earlier than 1 year after 
20
the date of enactment of this Act, the Secretary, in con-
21
sultation with the Secretary of the Treasury and the ap-
22
propriate Federal banking agencies, shall establish a pilot 
23
program to be known as the Eye Bond Pilot Program 
24
under which— 
25
21:50 May 17, 2019
H2620
6 
•HR 2620 IH
(1) the Director of the National Eye Institute 
1
shall, 
in 
accordance 
with 
section 
6, 
select 
2
translational research projects to be funded by eye 
3
bonds; and 
4
(2) the Secretary shall— 
5
(A) provide a partial Federal guarantee of 
6
the eye bonds; 
7
(B) contract with an issuer to issue the eye 
8
bonds; and 
9
(C) use the proceeds from the sale of the 
10
eye bonds to fund the selected projects and to 
11
pay for other related expenses, as permitted by 
12
this Act. 
13
(b) FEDERAL GUARANTEE.— 
14
(1) IN GENERAL.—The Secretary shall guar-
15
antee the payment of principal (but not the payment 
16
of interest) on an eye bond, on a bond-by-bond 
17
basis, in an amount to be determined by the Sec-
18
retary, but in no case may the amount of such guar-
19
antee be more than 50 percent of the principal of 
20
the eye bond. 
21
(2) PRIORITIZATION
OF
TAXPAYER
INTER-
22
ESTS.—All eye bonds shall be structured to give first 
23
priority to protecting the interests of the United 
24
States by ensuring that— 
25
21:50 May 17, 2019
H2620
7 
•HR 2620 IH
(A) all cash proceeds received from the re-
1
payment of an eye bond are first used to reduce 
2
the amount of principal guaranteed by the Sec-
3
retary under the terms of the eye bond; and 
4
(B) the Secretary has a senior claim on all 
5
assets and collateral under the eye bond to the 
6
extent the guarantee provided by the Secretary 
7
is not extinguished. 
8
(3) LIMITATION.—The Secretary may not guar-
9
antee— 
10
(A) more than $1,000,000,000 for all eye 
11
bonds issued pursuant to this Act; and 
12
(B) more than $250,000,000 for all eye 
13
bonds issued pursuant to this Act in any single 
14
fiscal year. 
15
(c) ISSUANCE SCHEDULE.—The Secretary shall, in 
16
consultation with the Secretary of the Treasury and 
17
issuers, establish a schedule for the issuance of eye bonds 
18
that ensures that funded projects represent a reasonable 
19
sample of diverse causes of vision loss. 
20
(d) RISK-SHARE POOL.— 
21
(1) IN GENERAL.—With respect to an eye bond 
22
guaranteed under this section, the Secretary may 
23
allow a risk-share pool capitalized by issuers to pro-
24
vide a first-loss guarantee of the principal and inter-
25
21:50 May 17, 2019
H2620
8 
•HR 2620 IH
est of such bond, if the Secretary determines that 
1
such first-loss guarantee would— 
2
(A) be a robust source of protection for the 
3
United States, as guarantor of the eye bond, 
4
that reduces the cost of the Federal guarantee 
5
to the United States; 
6
(B) encourage the flow of private sector 
7
capital into biomedical translational research; 
8
(C) create a prudent incentive for issuers 
9
to contribute additional private capital for bio-
10
medical translational research; or 
11
(D) meet other public interest, safety, and 
12
soundness goals. 
13
(2) CONSULTATION.—In making a determina-
14
tion under paragraph (1), the Secretary shall consult 
15
with the Secretary of the Treasury and the appro-
16
priate Federal banking agencies. 
17
(3) FUNDING.—The cost of contracting with a 
18
risk-share pool under this subsection shall be paid 
19
from the proceeds from the sale of eye bonds pursu-
20
ant to the Program. 
21
(e) EQUITY
OPTION
FOR
THE
SEC-
22
RETARY.— 
23
(1) IN GENERAL.—With respect to an eye bond 
24
issued pursuant to this Act, the Secretary, in con-
25
21:50 May 17, 2019
H2620
9 
•HR 2620 IH
sultation with the Secretary of the Treasury and 
1
other appropriate parties, including eye bond issuers 
2
and investors, may negotiate an equity position for 
3
the United States Government in the projects to be 
4
funded by such eye bond if the Secretary determines 
5
that such an equity position will further the interests 
6
of the Program and the United States. 
7
(2) LIMITATIONS.— 
8
(A) SUPPLEMENTAL.—Any equity position 
9
taken in a project pursuant to paragraph (1) 
10
shall be supplemental to, not in lieu of, a guar-
11
antee provided by the Secretary with respect to 
12
the eye bond funding such project. 
13
(B) TOTAL AMOUNT.—The total of amount 
14
of an eye bond guarantee under this section and 
15
any equity position taken by the Secretary in a 
16
project funded by such bond that is supple-
17
mental to such guarantee shall not exceed 50 
18
percent of the principal amount of the eye 
19
bond. 
20
(3) NOTIFICATION AND CONSULTATION.—Prior 
21
to finalization of any equity position under para-
22
graph (1), the Secretary shall notify the applicable 
23
congressional committees and consult with such 
24
committees on the proposed terms of such equity po-
25
21:50 May 17, 2019
H2620
10 
•HR 2620 IH
sition and whether taking such equity position will 
1
further the interests of the Program and the United 
2
States. 
3
(f) TERMINATION OF THE PROGRAM.— 
4
(1) IN GENERAL.—Except as provided in para-
5
graph (2), the Program shall terminate on the date 
6
that is 6 years after the date of enactment of this 
7
Act. 
8
(2) EARLY TERMINATION.— 
9
(A) IN GENERAL.—The Secretary may ter-
10
minate the Program before the date described 
11
in paragraph (1). 
12
(B) CONGRESSIONAL
NOTIFICATION.—If 
13
the Secretary determines that the Program 
14
shall be terminated under subparagraph (A), 
15
not later than 60 days before the date on which 
16
the termination is effective, the Secretary 
17
shall— 
18
(i) submit to the applicable congres-
19
sional committees a report that includes— 
20
(I) a description of the reasons 
21
for the termination; 
22
(II) any corrective actions that 
23
may be taken; and 
24
21:50 May 17, 2019
H2620
11 
•HR 2620 IH
(III) any other actions that may 
1
be taken to promote the use of private 
2
capital and to increase the amount of 
3
Federal funds made available to carry 
4
out basic and translational biomedical 
5
research; and 
6
(ii) make publicly available the report 
7
described in clause (i). 
8
(3) EFFECT ON EYE BONDS ISSUED AND FED-
9
ERAL GUARANTEES.—The termination of the Pro-
10
gram shall not affect the validity of— 
11
(A) any eye bond issued before the date on 
12
which the Program is terminated; or 
13
(B) any Federal guarantee under this Act 
14
for an eye bond described in subparagraph (A). 
15
(g) PROGRAM FUNDING.— 
16
(1) ADMINISTRATIVE
EXPENSES
PAID
FROM 
17
BOND SALES.—Except as provided under paragraph 
18
(2), the cost of carrying out this Act, including the 
19
cost to the Secretary in administering the Program, 
20
shall be recovered from the proceeds from the sale 
21
of eye bonds pursuant to the Program or from fees 
22
as set forth in paragraph (3). 
23
21:50 May 17, 2019
H2620
12 
•HR 2620 IH
(2) SPECIFIC
APPROPRIATION
OR
CONTRIBU-
1
TION.—No guarantee shall be made under this sec-
2
tion unless— 
3
(A) an appropriation for the full cost of 
4
the guarantee has been made; 
5
(B) the Secretary has received from the 
6
eye bond issuer a payment in full for the cost 
7
of the guarantee; or 
8
(C) a combination of an appropriation and 
9
the deposit of a payment from the bond issuer 
10
into the Treasury has been made in a sufficient 
11
amount to cover the full cost of the guarantee. 
12
(3) COST OF GUARANTEES.— 
13
(A) IN
GENERAL.—The Secretary shall 
14
charge and collect fees for guarantees under 
15
this section in amounts the Secretary deter-
16
mines are sufficient to recover applicable ad-
17
ministrative expenses. 
18
(B) AVAILABILITY.—Fees collected under 
19
this subsection— 
20
(i) shall be deposited by the Secretary 
21
into the Treasury; and 
22
(ii) are authorized to remain available 
23
until expended. 
24
21:50 May 17, 2019
H2620
13 
•HR 2620 IH
SEC. 4. EYE BOND TERMS, CONDITIONS, AND STRUCTURE. 
1
(a) IN GENERAL.—Not later than 180 days after the 
2
date of enactment of this Act, the Secretary, in consulta-
3
tion with the Secretary of the Treasury, the Chairman of 
4
the Securities and Exchange Commission, the heads of the 
5
appropriate Federal banking agencies, the Director of the 
6
National Institutes of Health, and the heads of other Fed-
7
eral departments and agencies and other interested parties 
8
as the Secretary determines appropriate, shall issue regu-
9
lations to specify the terms, conditions, and structure for 
10
an eye bond. 
11
(b) AUCTIONS.—In issuing the regulations under 
12
subsection (a)— 
13
(1) the Secretary may provide for an auction to 
14
select the purchasers of eye bonds; and 
15
(2) any such auction may include a process that 
16
minimizes the risk to the Government of the Federal 
17
guarantee involved by allowing bidders for an eye 
18
bond to compete against each other by bidding on 
19
the percentage of the Federal guarantee under sec-
20
tion 4(b) with respect to the eye bond, with the bid 
21
for the lowest percentage winning the auction, tak-
22
ing into account other terms and conditions set by 
23
the issuer to ensure the lowest total cost to the Gov-
24
ernment. 
25
21:50 May 17, 2019
H2620
14 
•HR 2620 IH
SEC. 5. EYE BOND ISSUERS. 
1
(a) ISSUER CRITERIA.—Not later than 180 days 
2
after the date of enactment of this Act, the Secretary, in 
3
consultation with the Secretary of the Treasury, shall 
4
issue regulations— 
5
(1) to establish the criteria for selecting issuers; 
6
(2) to ensure that issuers perform in a manner 
7
that ensures the successful issuance of eye bonds 
8
that promote biomedical translational research in the 
9
United States; and 
10
(3) to ensure that issuers use sound under-
11
writing practices that protect the interests of— 
12
(A) the United States; 
13
(B) eye bond investors; and 
14
(C) 
the 
long-term 
promotion 
of 
15
translational research for vision impairment 
16
and other diseases, disabilities, and syndromes 
17
congenital to vision impairment or caused by vi-
18
sion impairment, taking into account features 
19
that are valuable after any authorization for ex-
20
panded use of a limited Federal guarantee for 
21
biomedical translational research for other dis-
22
eases and disabilities. 
23
(b) COMPENSATION FOR ISSUERS.—The issuer of an 
24
eye bond shall be compensated from the proceeds from the 
25
21:50 May 17, 2019
H2620
15 
•HR 2620 IH
sale of such eye bond at such rate and on such terms as 
1
the Secretary may provide. 
2
(c) PUBLIC DISCLOSURES WITH RESPECT TO EYE 
3
BONDS.— 
4
(1) IN
GENERAL.—Not less than 2 business 
5
days before the date on which an issuer issues an 
6
eye bond, the issuer shall file with the Securities and 
7
Exchange Commission, and make available to the 
8
public, the following information: 
9
(A) The nature of all projects funded by 
10
the eye bond. 
11
(B) The name of any principal individual 
12
or institution that will be conducting each 
13
project. 
14
(C) The milestones established for each 
15
project. 
16
(D) A determination by the issuer as to 
17
whether each project funded by the eye bond 
18
has appropriately protected intellectual prop-
19
erty. 
20
(E) The structure of the eye bond. 
21
(F) The interest payment schedule for the 
22
eye bond. 
23
(G) The anticipated returns and risks of 
24
the eye bond. 
25
21:50 May 17, 2019
H2620
16 
•HR 2620 IH
(H) Such other information as the Com-
1
mission determines necessary or appropriate in 
2
the public interest or for the protection of in-
3
vestors. 
4
(2) RULEMAKING.— 
5
(A) IN
GENERAL.—Not later than 180 
6
days after the date of enactment of this Act, 
7
the Securities and Exchange Commission shall 
8
issue regulations to carry out this subsection. 
9
(B) AUTHORITY OF THE SECRETARY.—If 
10
the Securities and Exchange Commission does 
11
not issue the regulations required under sub-
12
paragraph (A) before the end of the 180-day 
13
period described under subparagraph (A), the 
14
Secretary shall issue regulations to carry out 
15
this subsection before the end of the 60-day pe-
16
riod beginning on the end of the 180-day period 
17
described under subparagraph (A). 
18
SEC. 6. TRANSLATIONAL RESEARCH PROJECTS. 
19
(a) ELIGIBILITY REQUIREMENTS.—Not later than 
20
180 days after the date of enactment of this Act, the Sec-
21
retary, in consultation with the Secretary of the Treasury, 
22
the Director of the National Eye Institute, and other in-
23
terested parties, shall issue final regulations for the eligi-
24
bility criteria for selecting translational research projects 
25
21:50 May 17, 2019
H2620
17 
•HR 2620 IH
that will be funded through eye bonds. Such regulations 
1
shall address— 
2
(1) the stage of clinical trial for projects to pro-
3
vide the greatest likelihood of commercial applica-
4
tion; 
5
(2) the variations among disease and conditions 
6
needed to ensure sufficient diversification in each 
7
eye bond; and 
8
(3) the number of possible cures and treat-
9
ments that are needed as determined by the Sec-
10
retary, in consultation with issuers and the Director 
11
of the National Eye Institute, to ensure the success-
12
ful issuance of eye bonds so as to protect the United 
13
States as guarantor of the eye bonds, including— 
14
(A) drug therapies; 
15
(B) gene therapies; and 
16
(C) artificial restoration of sight and simi-
17
lar mechanisms. 
18
(b) SELECTION OF PROJECTS.— 
19
(1) IN GENERAL.—The Director of the National 
20
Eye Institute, in consultation with the Director of 
21
the National Institutes of Health and the Secretary 
22
of the Treasury, shall select translational research 
23
projects to be funded with the proceeds of an eye 
24
bond. 
25
21:50 May 17, 2019
H2620
18 
•HR 2620 IH
(2) FACTORS FOR SELECTION.—Not later than 
1
30 days after the date on which the final regulations 
2
are issued under subsection (a), the Secretary shall 
3
submit to the Director of the National Eye Institute 
4
factors that the Director of the National Eye Insti-
5
tute shall consider in making the selection under 
6
paragraph (1), including— 
7
(A) the amount of equity any intellectual 
8
property holder will hold in the project; 
9
(B) the resources any individual or institu-
10
tion will be required to demonstrate to ensure 
11
the ability of the individual or institution to 
12
repay the obligation under the eye bond, re-
13
gardless of the success or failure of the project 
14
funded with the proceeds of the eye bond; 
15
(C) the number of projects needed to en-
16
sure diversification of risk; 
17
(D) the manner in which funded projects 
18
will be defunded if the interim goals of the 
19
project are not satisfied; and 
20
(E) such other factors related to bio-
21
medical translational research project selection 
22
as the Secretary determines appropriate. 
23
(3) ADDITIONAL CONSULTATIONS.— 
24
21:50 May 17, 2019
H2620
19 
•HR 2620 IH
(A) IN GENERAL.—In carrying out para-
1
graph (1), the Director of the National Eye In-
2
stitute may establish any consultative body that 
3
the Director determines is necessary to provide 
4
for a complete, transparent, and forward-look-
5
ing selection of projects. 
6
(B) SCIENTIFIC
ADVISERS.—In carrying 
7
out paragraph (1), the Director of the National 
8
Eye Institute may consult with any group of 
9
scientific advisers that the Director determines 
10
is necessary. 
11
(c) ESTABLISHMENT OF MILESTONES.— 
12
(1) IN GENERAL.—The Director of the National 
13
Eye Institute shall, for each project funded by an 
14
eye bond, establish milestones to determine the prob-
15
ability of success or failure for such project. 
16
(2) INCLUSION IN FILINGS.—The Director of 
17
the National Eye Institute shall submit to the issuer 
18
of an eye bond the milestones for each project fund-
19
ed from such eye bond, so such milestones may be 
20
included in the filings made available by the issuer 
21
to the public under section 5(c). 
22
(d) RESEARCH REQUIREMENT.—Translational re-
23
search carried out under a project funded by an eye bond 
24
shall be conducted— 
25
21:50 May 17, 2019
H2620
20 
•HR 2620 IH
(1) in a State; and 
1
(2) by an individual or institution that is— 
2
(A) chartered in accordance with the laws 
3
of that State; and 
4
(B) clearly subject to verification of bene-
5
ficial ownership by the issuer and, upon re-
6
quest, by the Secretary. 
7
SEC. 7. INAPPLICABILITY OF CERTAIN LAWS. 
8
Eye bonds shall not be subject to— 
9
(1) section 15G of the Securities Exchange Act 
10
of 1934 (15 U.S.C. 78o–11); 
11
(2) except as provided under section 5(c), any 
12
registration or disclosure requirement promulgated 
13
by the Securities and Exchange Commission; and 
14
(3) section 13 of the Bank Holding Company 
15
Act of 1956 (12 U.S.C. 1851). 
16
SEC. 8. REPORTS. 
17
(a) GAO STUDY
AND REPORTS
ON OTHER RE-
18
SEARCH PROJECTS.— 
19
(1) ONGOING
STUDY.—The Comptroller Gen-
20
eral of the United States shall carry out an ongoing 
21
study to consider whether a program similar to the 
22
Eye Bond Pilot Program under this Act should be 
23
established for other biomedical research projects. 
24
21:50 May 17, 2019
H2620
21 
•HR 2620 IH
(2) REPORT.—The Comptroller General shall, 
1
during the period beginning on the date of the estab-
2
lishment of the Program and ending on the termi-
3
nation date of the Program, issue a report to the ap-
4
plicable congressional committees, not less frequently 
5
than annually, on all findings and determinations 
6
made in carrying out the study required under para-
7
graph (1). 
8
(b) REPORTS ON THE PROGRAM.—Not later than 2 
9
years after the date on which eye bonds are first issued 
10
under this Act, and annually thereafter during the period 
11
ending on the date that is 4 years after the date on which 
12
eye bonds are first issued under this Act, the Comptroller 
13
General and the Director of the National Institutes of 
14
Health (in consultation with the Director of the National 
15
Center for Advancing Translational Sciences) shall each 
16
issue a separate report to the applicable congressional 
17
committees on— 
18
(1) the progress of the issuance of eye bonds; 
19
(2) the reasons for any problems achieving de-
20
sired volumes of eye bonds or the ability of the Pro-
21
gram to proceed at a faster pace; 
22
(3) an analysis of the risk to the Government 
23
in providing the Federal guarantee described under 
24
section 4(b); 
25
21:50 May 17, 2019
H2620
22 
•HR 2620 IH
(4) any improvements to eye bonds that the 
1
Secretary should consider; 
2
(5) the applicability of financial instruments 
3
similar to eye bonds to other biomedical research 
4
areas such as cancer, Alzheimer’s disease, rare dis-
5
eases or conditions (as defined in section 526 of the 
6
Federal Food, Drug, and Cosmetic Act (21 U.S.C. 
7
360bb)) and syndromes of particular concern to chil-
8
dren; and 
9
(6) any other matter that the Comptroller Gen-
10
eral or the Director, respectively, determines is ap-
11
propriate. 
12
Æ 
21:50 May 17, 2019
H2620
